Minocycline

Generic Name: Minocycline

Brand Names: Amzeeq, Arestin, Dynacin, Minocin, Minolira, Solodyn, Ximino, Zilxi

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₇N_₃O_₇

CAS Number: 10118-90-8

Unique Ingredient Identifier: FYY3R43WGO

Background: Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.

Minocycline was granted FDA approval on 30 June 1971.

Indication: Oral and topical minocycline are indicated to treat inflammatory lesions of acne vulgaris. Subgingival microspheres are indicated as an adjunct treatment in the reduction of pocket depth in adults with periodontitis. Oral and intravenous formulations are indicated to treat infections of susceptible microorganisms. These include rickettsiae, Mycoplasma pneumoniae, Chlamydia trachomatis, Chlamydophila psittaci, Chlamydia trachomatis, Ureaplasma urealyticum, Borrelia recurrentis, Haemophilus ducreyi, Yersinia pestis, Francisella tularensis, Vibrio cholerae, Campylobacter fetus, Brucella species, Bartonella bacilliformis, Klebsiella granulomatis, Escherichia coli, Enterobacter aerogenes, Shigella species, Acinetobacter species, Haemophilus influenzae, and Kelbsiella species.

Associated Conditions: Bartonellosis, Brucellosis, Campylobacter fetus, Chancroid, Cholera (Disorder), Conjunctivitis, Inclusion, Granuloma Inguinale, Lymphogranuloma Venereum, Nongonococcal urethritis, Periodontitis, Plague, Psittacosis, Q Fever, Relapsing Fever, Respiratory Tract Infections (RTI), Rickettsia Infections, Rickettsialpox, Rocky Mountain Spotted Fever, Trachoma, Tularemia, Typhus infections, Inflammatory lesions

Associated Therapies: -

Clinical Trials

Biomarkers of Neuroinflammation and Anti-Inflammatory Treatments in Major Depressive Disorder

Early Phase 1

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo
Drug: Minocycline
Drug: Celecoxib

First Posted Date: 2015-02-13

Last Posted Date: 2019-05-23

Lead Sponsor: Centre for Addiction and Mental Health

Target Recruit Count: 115

Registration Number: NCT02362529

Locations: 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada

The Effects of Minocycline in Opioid-maintained Patients

Not Applicable

Completed

Conditions: Opioid Dependence
Pain

Interventions: Drug: Placebo
Drug: Minocycline

First Posted Date: 2015-02-09

Last Posted Date: 2020-03-06

Lead Sponsor: Yale University

Target Recruit Count: 27

Registration Number: NCT02359006

Locations: 🇺🇸
VA Hospital, West Haven, Connecticut, United States

The Response of Pathogens to the Respective or Combined Treatment of SRP and Local Minocycline in Chronic Periodontitis

Phase 4

Completed

Conditions: Chronic Periodontitis

Interventions: Procedure: surface and root planning
Drug: minocycline

First Posted Date: 2015-02-04

Last Posted Date: 2015-12-02

Lead Sponsor: Zhejiang University

Target Recruit Count: 70

Registration Number: NCT02355977

Minocycline as an Adjunct for the Treatment of Depressive Symptoms: Pilot Randomized Controlled Trial

Phase 4

Completed

Conditions: Depressive Disorder
Mood Disorders
Depressive Disorder, Treatment Resistant
Antidepressive Agents

Interventions: Drug: Minocycline

First Posted Date: 2014-10-13

Last Posted Date: 2016-09-05

Lead Sponsor: Pakistan Institute of Living and Learning

Target Recruit Count: 41

Registration Number: NCT02263872

Locations: 🇵🇰
Abasi Shaheed Hospital, Karachi, Sindh, Pakistan
🇵🇰
Civil hospital Karachi, Karachi, Sindh, Pakistan
🇵🇰
Karwan-e-Hayat, Karachi, Sindh, Pakistan

Study 3: Minocycline Decreases Microglia Activation

Phase 2

Not yet recruiting

Conditions: Hypertension

Interventions: Drug: Minocycline

First Posted Date: 2014-08-11

Last Posted Date: 2023-05-09

Lead Sponsor: University of Florida

Target Recruit Count: 9

Registration Number: NCT02213575

Locations: 🇺🇸
UF Health Cardiovascular Clinic, Gainesville, Florida, United States

Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer

Phase 2

Completed

Conditions: Anxiety Disorder
Depression
Recurrent Breast Cancer
Stage IA Breast Cancer
Stage II Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Stage IB Breast Cancer
Stage IIIC Breast Cancer

Interventions: Drug: minocycline hydrochloride
Other: placebo
Other: laboratory biomarker analysis
Other: Questionnaire administration

First Posted Date: 2014-07-30

Last Posted Date: 2025-01-08

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 56

Registration Number: NCT02203552

Locations: 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States